Pricing in the Market for Anticancer Drugs
Bibliographic Data
In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab-brand name Yervoy-at $120,000 for a course of therapy. The drug was associated with an incremental increase in life expectancy of four months. Drugs like ipilimumab have fueled the perception that the launch prices of new anticancer drugs and other drugs in the so-called "specialty" pharmaceutical market have been increasing over time and that increases are unrelated to the magnitude of the expected health benefits. In this paper, we discuss the unique features of the market for anticancer drugs and assess trends in the launch prices for 58 anticancer drugs approved between 1995 and 2013 in the United States. We restrict attention to anticancer drugs because the use of median survival time as a primary outcome measure provides a common, objective scale for quantifying the incremental benefit of new products. We find that the average launch price of anticancer drugs, adjusted for inflation and health benefits, increased by 10 percent annually-or an average of $8,500 per year-from 1995 to 2013. We argue that the institutional features of the market for anticancer drugs enable manufacturers to set the prices of new products at or slightly above the prices of existing therapies, giving rise to an upward trend in launch prices. Government-mandated price discounts for certain classes of buyers may have also contributed to launch price increases as firms sought to offset the growth in the discount segment by setting higher prices for the remainder of the market
Business · Cancer · Drug prices · Economics · Ipilimumab · Life expectancy · Market share · Monetary economics · Economic and Financial Impacts of Cancer · Health Systems, Economic Evaluations, Quality of Life · Medicine · Pharmaceutical Economics and Policy · Internal Medicine · Marketing
Outcomes of the 340B Drug Pricing Program
Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L
Comparison of Cancer-Related Spending and Mortality Rates in the US vs 21 High-Income Countries
Launch and Postlaunch Price Developments of New Drugs in the US, Germany, and Switzerland
Pricing strategy research in the dual-channel pharmaceutical supply chain considering service
Les félicités du capital en santé
Price regulation and competition among on-patent anticancer drugs in Italy
The Advantages of Awarding the Federal Government Negotiating Power Over the Prices of Prescription Drugs
Costs and Benefits of Branded Drugs
Differential own-price elasticity of demand for prescription drugs by clinical value
Does Medicare Reimbursement Drive Up Drug Launch Prices
Killer Acquisitions
Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US
Profits over care? An analysis of the relationship between corporate capitalism in the healthcare industry and cancer mortality in the United States
Drug Pricing in the United States
Pay, Reference Points, and Police Performance
Mental Accounting and Consumer Choice
Strategic Pricing of New Pharmaceuticals
Rule-based price fairness and its effect on willingness to purchase
Are fairness constraints on profit-seeking important
Medical Care Costs
An Empirical Analysis of Latitude of Price Acceptance in Consumer Package Goods
| Unique citing works | 15 |
|---|---|
| Citations per year | 1,5 |
| Citation span | 2016 - 2026 (11) |
| Citation velocity | current |
| Highly cited | No |
| Citation types | Neutral: 14 |